Search

Your search keyword '"Farzaneh-Far, Ramin"' showing total 210 results

Search Constraints

Start Over You searched for: "Farzaneh-Far, Ramin" Remove constraint "Farzaneh-Far, Ramin"
210 results on '"Farzaneh-Far, Ramin"'

Search Results

1. Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial.

2. Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial

3. Correction: Change in Leukocyte Telomere Length Predicts Mortality in Patients with Stable Coronary Heart Disease from the Heart and Soul Study

4. Change in Leukocyte Telomere Length Predicts Mortality in Patients with Stable Coronary Heart Disease from the Heart and Soul Study.

5. Prognostic value of electrocardiographic detection of unrecognized myocardial infarction in persons with stable coronary artery disease: data from the Heart and Soul Study

6. A functional polymorphism in renalase (Glu37Asp) is associated with cardiac hypertrophy, dysfunction, and ischemia: data from the heart and soul study.

7. Telomere length trajectory and its determinants in persons with coronary artery disease: longitudinal findings from the heart and soul study.

8. Phase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria

15. Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody–Positive Generalized Myasthenia Gravis

16. Zilucoplan:An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody–Positive Generalized Myasthenia Gravis

19. Association of marine omega-3 fatty acid levels with telomeric aging in patients with coronary heart disease

21. Thinking outside the box

24. Use of ranolazine in patients with incomplete revascularization after percutaneous coronary intervention: Design and rationale of the Ranolazine for Incomplete Vessel Revascularization Post–Percutaneous Coronary Intervention (RIVER-PCI) trial

25. Correlation of Quantitative Myasthenia Gravis and Myasthenia Gravis Activities of Daily Living scales in the MGTX study.

26. Cross-sectional analysis of the Myasthenia Gravis Patient Registry: Disability and treatment.

30. Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial

32. Glomerular membrane attack complex is not a reliable marker of ongoing C5 activation in lupus nephritis

33. Body mass index is negatively associated with telomere length: a collaborative cross-sectional meta-analysis of 87 observational studies

34. Body mass index is negatively associated with telomere length: a collaborative cross-sectional meta-analysis of 87 observational studies

35. RA101495, A Subcutaneously Administered Peptide Inhibitor of Complement Component 5 (C5) for the Treatment of Generalized Myasthenia Gravis (gMG): Phase 1 Results and Phase 2 Design (S31.006)

36. The spectrum of complement C9 staining in lupus nephritis

37. Biological ageing-a potentially modifiable risk factor for CAD?

38. Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization Results From the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial

41. Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization

42. Association of cardiorespiratory fitness with left ventricular remodeling and diastolic function: the Cooper Center Longitudinal Study

43. Effects of Ranolazine in Patients With Chronic Angina in Patients With and Without Percutaneous Coronary Intervention for Acute Coronary Syndrome: Observations From the MERLIN-TIMI 36 Trial

44. Development of an echocardiographic risk-stratification index to predict heart failure in patients with stable coronary artery disease: the Heart and Soul study

Catalog

Books, media, physical & digital resources